Liraglutide: Research Profile, Dosages & Supplier Prices
Liraglutide is a glp-1 agonist compound with a molecular weight of 3751.2 g/mol and a research half-life of approximately 13 hours in published human pharmacokinetic data. Liraglutide is a once-daily GLP-1 receptor agonist peptide, the active ingredient in Victoza and Saxenda. It was the first GLP-1 agonist with published cardiovascular outcomes data (the LEADER trial) and remains a reference compound in metabolic research.
Research Use Only (RUO). Not for human or veterinary use. Not medical advice.
| Sequence | GLP-1(7-37) with Arg34 and C16 fatty acid chain at Lys26 |
| Formula | C172H265N43O51 |
| Mol. weight | 3751.2 g/mol |
| Half-life | Approximately 13 hours in published human pharmacokinetic data |
| Forms sold | Lyophilized vial (research); pre-filled pens (pharmaceutical) |
What is Liraglutide?
Research interest covers GLP-1 pharmacology, daily versus weekly incretin kinetics, and comparative studies against semaglutide (the SCALE and STEP programs published head-to-head data).
Liraglutide is a complex fatty-acid-modified synthesis. Verify third-party mass spec identity (3751.2 g/mol) on batch COAs.
Mechanism of Action (Research Context)
GLP-1 receptor agonist with C16 fatty-acid-mediated albumin binding enabling once-daily kinetics in research models.
Research Areas
Liraglutide Dosages in Research
Published clinical research used once-daily doses titrated to 1.8mg (Victoza) or 3.0mg (Saxenda) in human trials. Laboratory research use only.
Dosage information is a summary of published laboratory research and is provided for informational purposes only. These compounds are not for human use.
Storage & Handling
Lyophilized: -20C. Reconstituted: 2-8C, use within 30 days. Do not freeze after reconstitution.
Liraglutide Supplier Price Comparison
No tracked suppliers stock Liraglutide yet — inventory syncs run continuously. Check our supplier reviews.